Results 161 to 170 of about 646,127 (297)

PET Imaging in Alzheimer Disease in the Era of Antiamyloid Therapy in the United States: Clinical Utility, Quantification, and Policy Landscape. [PDF]

J Nucl Med Technol
Skyles T, Bouchal SM, Giarratana A, Wengler J, Hart I, Greig E, Singh H, Huang SS, Martinez F, Nguyen B, Shin CH, Yang M, Parent E, Robb WH, Franceschi AM, Burkett B, Johnson D, Koran ME.   +17 more
europepmc   +1 more source

Tau Pathology in Alzheimer's Disease Uniquely Affects Sulcal Depths

Annals of Neurology, EarlyView.
Objective Though it is widely known that tau deposition affects brain structure, the precise localization of these effects is poorly understood, especially in relation to gyral and sulcal anatomy. We investigated whether tau pathology in Alzheimer's disease (AD) preferentially affects sulci, and particularly sulcal depths.
Samira A. Maboudian, Corrina S. Fonseca, Adam C. Martersteck, Yishu Chao, Yuheng Chen, Daniela Ushizima, Duygu Tosun, Lea T. Grinberg, Kevin S. Weiner, William J. Jagust, for the Alzheimer's Disease Neuroimaging Initiative   +10 more
wiley   +1 more source

Endomyocardial Biopsy Revisited: Diagnostic Value and Expanding Roles in Cardiac Amyloidosis. [PDF]

Curr Heart Fail Rep
Schwarting SK, Aus dem Siepen F.
europepmc   +1 more source

Individualized Atrophy‐Based Prediction of Dementia Progression in Familial Frontotemporal Lobar Degeneration With Bayesian Linear Mixed‐Effects Modeling

Annals of Neurology, EarlyView.
Objective Age of symptom onset is highly variable in familial frontotemporal lobar degeneration (f‐FTLD). Accurate prediction of onset would inform clinical management and trial enrollment. Prior studies indicate that individualized maps of brain atrophy can predict conversion to dementia in f‐FTLD.
Shubir Dutt, Dana Leichter, Yann Cobigo, Amy Wolf, John Kornak, Annie Clark, Lucy L. Russell, Arabella Bouzigues, David M. Cash, Martina Bocchetta, Molly Olzinski, Brian Appleby, Ece Bayram, Barbara Borroni, Andrea Bozoki, Chris R. Butler, David Clark, Rhian S. Convery, R. Ryan Darby, Alexandre de Mendonça, Bradford Dickerson, Kimiko Domoto‐Reilly, Simon Ducharme, Eve Ferry‐Bolder, Elizabeth Finger, Phoebe H. Foster, Douglas R. Galasko, Daniela Galimberti, Alexander Gerhard, Nupur Ghoshal, Caroline Graff, Neill Graff‐Radford, Ian M. Grant, Chadwick M. Hales, Lawrence S. Honig, Ging‐Yuek Hsiung, Edward D. Huey, David Irwin, Lize C. Jiskoot, Walter Kremers, Justin Y. Kwan, Robert Laforce, Isabelle Le Ber, Gabriel C. Léger, Johannes Levin, Irene Litvan, Ian R. Mackenzie, Mario Masellis, Mario F. Mendez, Fermin Moreno, Chiadi Onyike, Markus Otto, Belen Pascual, Peter Pressman, Rosa Rademakers, Eliana Marisa Ramos, Aaron Ritter, Erik D. Roberson, James B. Rowe, Raquel Sanchez‐Valle, Isabel Santana, Harro Seelaar, Allison Snyder, Sandro Sorbi, Matthis Synofzik, Maria Carmela Tartaglia, Pietro Tiraboschi, John C. van Swieten, Marijne Vandebergh, Rik Vandenberghe, Hilary W. Heuer, Bruce L. Miller, William W. Seeley, Maria Luisa Gorno‐Tempini, Joel H. Kramer, Leah Forsberg, Kejal Kantarci, Bradley F. Boeve, Adam L. Boxer, Jonathan D. Rohrer, Howard J. Rosen, Adam M. Staffaroni, FTD Prevention Initiative (FPI) investigators   +82 more
wiley   +1 more source

Cardiac phenotype in hereditary transthyretin amyloidosis: correlations between fibril types and 99mTc-DPD uptake. [PDF]

Sci Rep
Löfbacka V, Wixner J, Westermark P, Vesterlund JD, Anan I, Pilebro B.   +5 more
europepmc   +1 more source

Temporal Modeling of Amyloid and Tau Trajectories in Alzheimer's Disease Using PET and Plasma Biomarkers

Annals of Neurology, EarlyView.
Objective This study aimed to compare positron emission tomography (PET) and plasma‐based temporal modeling of amyloid and tau biomarkers in Alzheimer's disease. Methods Longitudinal amyloid PET (n = 1,097, mean age ± SD = 72.5 ± 7.38 year, 51.4% male), 18F‐flortaucipir tau‐PET (n = 230, 74.3 ± 7.18 year, 52.2% female), and Fujirebio Lumipulse plasma p‐
Christopher A. Brown, Katheryn A.Q. Cousins, Magdalena Korecka, Emily McGrew, Alice Chen‐Plotkin, John A. Detre, Corey T. McMillan, Edward B. Lee, Sandhitsu R. Das, Dawn Mechanic‐Hamilton, Paul A. Yushkevich, Ilya M. Nasrallah, Leslie M. Shaw, for the Alzheimer's Disease Neuroimaging Initiative, David A. Wolk   +14 more
wiley   +1 more source

Control Strategies in Guanine Biocrystallization

Angewandte Chemie, EarlyView.
Biological guanine crystals produce spectacular photonic phenomena in animals and hold great promise as new, sustainable optical materials. We review how organisms precisely control the structure, morphologies, and resulting optical properties of these crystals using a set of ingenious ‘design’ strategies, including control of pH, template‐directed ...
Shashanka S. Indri, Avital Wagner, Benjamin A. Palmer   +2 more
wiley   +2 more sources

Current Standards and Perspectives in Proteomics for Cardiac Amyloidosis. [PDF]

Anal Chem
Greco F, McPhail E, Canetti D, Masri A, Ferrari Chen YF, Menichetti L, Aimo A, Franzini M, Ciccone L, Pucci A, Castiglione V, Limongelli G, Merlo M, Sinagra G, Basso C, Fontana M, Gillmore JD, McDonnell LA, Emdin M, Merlini G, Vergaro G.   +20 more
europepmc   +1 more source

Novel Monoclonal Antibody Detects Small Aβ Oligomers More Sensitively Than Lecanemab in Alzheimer's Disease CSF, Serum and Culture Media

Annals of Neurology, EarlyView.
Objective Aqueously diffusible oligomers of the amyloid β‐protein (oAβ) are neurotoxic and play a role in neuronal dysfunction in Alzheimer's disease (AD). Accurate quantification of oAβ in brains and biofluids could be valuable for understanding and monitoring AD.
Yi Ran Xu, Youqi Tao, Alexandra M. Lish, Shaomin Li, Beth L. Ostaszewski, Amirah K. Anderson, Tracy Young‐Pearse, Trebor L. Lawton, Hyun‐Sik Yang, Dominic M. Walsh, Ting Yang, Dennis J. Selkoe   +11 more
wiley   +1 more source

Development and characterization of chimeric antigen receptor macrophages for amyloid clearance. [PDF]

Front Immunol
Balachandran M, Foster JS, Hancock TJ, Martin EB, Jackson JW, Angell N, Wall JS.   +6 more
europepmc   +1 more source